Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 123
Filtrar
1.
Ocul Immunol Inflamm ; : 1-12, 2019 Nov 11.
Artigo em Inglês | MEDLINE | ID: mdl-31710514

RESUMO

Purpose: To estimate the incidence rate (IR) and identify risk factors associated to inflammatory relapse after immunosuppressive drug (ISD) discontinuation in noninfectious uveitis patients.Methods: Multicenter longitudinal retrospective study, including patients from four uveitis clinics followed-up until December 2018. Hazard ratios for different variables were estimated using multivariable Cox models.Results: 32 patients (34 episodes of ISD discontinuation) were analyzed (median and maximum follow-up time: 2.4 and 19.2 years, respectively). Fourteen patients presented at least one relapse: anterior (8 patients), intermediate (5) and posterior (8). IR (95% confidence interval) of the first relapse was 14.3 (8.6-23.8) episodes per 100 patient-years (median survival time: 4.8 years). Early use of ISDs, panuveitis, and higher oral corticosteroid dosage at discontinuation were associated with higher hazards of relapse in multivariable analysis.Conclusions: Relapse is a frequent and early event after ISD discontinuation. Identifying relapse risk factors could support the physician's decision regarding ISD discontinuation.

2.
Immunotherapy ; 11(13): 1107-1116, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31378114

RESUMO

Background: Mesenchymal stem cells (MSCs) are a promising treatment of different musculoskeletal diseases including osteoarthritis and rheumatoid arthritis (RA). Results from different approaches in this treatment have been not conclusive. Aim: To analyze factors related to interactions between peripheral blood mononuclear cells (PBMCs) and MSCs and the influence of cellular activation. Materials & methods: PBMCs from RA patients and healthy controls (HC) were obtained. MSCs from bone marrow (BM-MSCs) were obtained from six donors. CD4, CD25, CD69 and CD127 expression was measured by flow cytometry. Repeated measures analysis of variance (ANOVA) models were performed using activation, co-culture with BM-MSCs and time of culture (24 h, 72 h, 6 days) as within-subject variables. Results: PBMCs activated and co-cultured with BM-MSCs showed a lower proportion of CD25-positive and CD25high/CD127low-negative cells in both RA and HC. Additionally, a maintained expression of CD69 was also observed in RA and HC when PBMCs were activated and co-cultured with BM-MSCs. Conclusion: Both PBMC activation grade and RA disease activity influence the immunomodulatory effect of BM-MSCs on T-cell activation.

3.
Graefes Arch Clin Exp Ophthalmol ; 257(11): 2505-2516, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31385033

RESUMO

PURPOSE: To compare the clinical prognosis among selected white dot syndromes (WDS) (birdshot chorioretinopathy (BRC), multifocal choroiditis, serpiginous choroidopathy (SC), and others) and to identify risk factors of poor visual prognosis. METHODS: Retrospective longitudinal cohort study including 84 patients (143 affected eyes) diagnosed with WDS between 1982 and July 2017, followed up until loss of follow-up or December 2017, and recruited from three Uveitis Clinics (Madrid Community, Spain). Our main outcome measures were temporary or permanent moderate (corrected visual acuity in the Snellen scale < 20/50) or severe (< 20/200) vision losses, and development of new ocular complications. Incidence rates (IR) of the main outcome measures were estimated per 100 eye-years. Bivariate and multivariate Cox robust regression models analyzed the association of demographic- and clinical-related variables with vision loss. RESULTS: SC exhibited the greatest IR of vision loss, even in the multivariate models. Previous events of vision loss, presence of choroidal neovascularization, and cataracts exhibited worse visual prognosis. Monotherapy with immunosuppressive drugs but not combine therapy was also associated with higher IR of visual loss. Regarding new ocular complications, BRC showed the highest IR of epiretinal membrane and macular edema. CONCLUSIONS: SC presents the worst visual prognosis. Some ocular manifestations can identify patients with WDS at risk of a worse clinical evolution.

4.
Trials ; 20(1): 387, 2019 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-31262366

RESUMO

PURPOSE: The purpose of the study was to compare the safety and efficacy of autologous mesenchymal stem cells (MSCs) embedded in a xenogenic scaffold for repairing the supraspinatus tendon. METHODS: This was a randomized, double-blind and placebo-controlled trial evaluating patients with full-thickness rotator cuff tears (Eudra-CT, 2007-007630-19). Effectiveness was evaluated using the Constant score and a visual analogue pain scale (VAS). Constant score has four domains including pain (15 possible points), activities of daily living (20 possible points), mobility (40 possible points), and strength (25 possible points). Scores range from 0 points (most disability) to 100 points (least disability). The structural integrity of the repaired tendon was assessed by magnetic resonance imaging (MRI) according to Patte and Thomazeau classification criteria. The primary study end point was an improvement in the Constant score by 20 points at one year compared to initial assessment. RESULTS: The trial was stopped due to adverse effects observed in both groups. Only thirteen patients were included and analyzed. The Constant questionnaire showed a significant improvement in the MSC treatment group compared with the preoperative data (p = 0.0073). Secondary outcome measures were similar in both groups. CONCLUSIONS: Our study showed preliminary inconclusive clinical outcomes in the patients treated with MSCs. Adverse events revealed the need for further approaches using scaffolds of a different nature or perhaps no scaffolds, in the context of small joints. TRIAL REGISTRATION: Eudra-CT, 2007-007630-19 . Registered on 30 January 2008. LEVEL OF EVIDENCE: A Level 1 of evidence treatment study.

5.
Arthritis Res Ther ; 21(1): 112, 2019 May 06.
Artigo em Inglês | MEDLINE | ID: mdl-31060598

RESUMO

INTRODUCTION: Mesenchymal stem cells (MSCs) have the ability to differentiate into different types of cells of the mesenchymal lineage, such as osteocytes, chondrocytes, and adipocytes. It is also known that under inflammatory stimuli or in the appropriate experimental conditions, they can also act as regulators of inflammation. Thus, in addition to their regenerating potential, their interest has been extended to their possible use in cell therapy strategies for treatment of immune disorders. OBJECTIVE: To analyze, by RNA-seq analysis, the transcriptome profiling of allogenic MSCs under RA lymphocyte activation. METHODS: We identified the differentially expressed genes in bone marrow mesenchymal stem cells after exposure to an inflammatory environment. The transcriptome profiling was evaluated by means of the precise measurement of transcripts provided by the RNA-Seq technology. RESULTS: Our results evidenced the existence of blocking of both regenerative (differentiation) and immunomodulatory phenotypes under inflammatory conditions characterized by an upregulation of genes involved in immune processes and a simultaneous downregulation of genes mainly involved in regenerative or cell differentiation functions. CONCLUSIONS: We conclude that the two main functions of MSCs (immunomodulation and differentiation) are blocked, at least while the inflammation is being resolved. Inflammation, at least partially mediated by gamma-interferon, drives MSCs to a cellular distress adopting a defensive state. This knowledge could be of particular interest in cases where the damage to be repaired has an important immune-mediated component.

6.
Reumatol. clín. (Barc.) ; 15(2): 102-108, mar.-abr. 2019. tab, graf
Artigo em Inglês | LILACS-Express | ID: ibc-ET1-3371

RESUMO

Objectives: To describe the prevalence of comorbidities in patients with RA in Spain and discuss their management and implications using data from the Spanish cohort of the multinational study on COMOrbidities in Rheumatoid Arthritis (COMORA). Methods: This is a national sub-analysis of the COMORA study. We studied the demographics and disease characteristics of 200 adults patients diagnosed with RA (1987 ACR), and routine practices for screening and preventing the following selected comorbidities: cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and depression. Results: Patients had a mean age of 58 years and a mean RA duration of 10 years. Mean DAS28 score was 3.3 and approximately 25% of patients were in remission (DAS28 <2.6). Forty-four (22%) patients had ≥1 comorbidity, the most frequent being depression (27%) and obesity (26%). A history of myocardial infarction or stroke was observed in 5% and 1% of patients, respectively, and any solid tumor in 6%. Having a Framingham Risk Score >20% (51%), hypercholesterolemia (46%) or hypertension (41%) and smoking (25%) were the most common CV risk factors. For prostate, colon and skin cancers, only 9%, 10% and 18% of patients, respectively, were optimally monitored. Infections were also inadequately managed, with 7% and 17% of patients vaccinated against influenza and pneumococcal, respectively, as was osteoporosis, with 47% of patients supplemented with vitamin D and 56% with a bone densitometry performed. Conclusions: In Spain, the prevalence of comorbidities and CV risk factors in RA patients with established and advanced disease is relatively high, and their management in clinical daily practice remains suboptimal


Objetivos: Describir la prevalencia de comorbilidades en pacientes con AR en España y discutir sobre su manejo en la clínica diaria utilizando los datos de la cohorte española del estudio internacional COMORA. Métodos: Subanálisis nacional del estudio COMORA en el que se analizaron las características demográficas y clínicas de 200 pacientes con AR (1987 ACR) y las prácticas rutinarias para el cribado y la prevención de eventos cardiovasculares (CV), gastrointestinales y pulmonares, infecciones, cáncer, osteoporosis y depresión. Resultados: Los pacientes tenían una edad media de 58 años, una duración media de la enfermedad de 10 años, un DAS28 de 3,3 y el 25% estaba en remisión (DAS28 <2,6). El 22% de los pacientes presentaba al menos una comorbilidad, principalmente depresión (27%) y obesidad (26%). El 5% tenía historia de infarto de miocardio, el 1% de ictus y el 6% de tumor sólido. Una puntuación de Framingham >20% (51%), tener hipercolesterolemia (46%), hipertensión (41%) y fumar (25%) fueron los factores de riesgo CV más comunes. En relación con el cáncer de próstata, colon y piel, solo el 9, 10 y el 18% de los pacientes, respectivamente, estaban óptimamente controlados. Las infecciones tampoco se manejaban de forma óptima, con solo el 7 y el 17% de los pacientes vacunados contra la influenza y neumococo, respectivamente, al igual que la osteoporosis, con el 47% suplementados con la vitamina D y el 56% con una densitometría realizada. Conclusiones: En España, la prevalencia de comorbilidades y factores de riesgo CV en pacientes con AR establecida y avanzada es relativamente alta, y su manejo en la clínica diaria continúa siendo subóptimo

7.
Sci Rep ; 9(1): 2777, 2019 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-30808881

RESUMO

Behçet's disease (BD) is an immune-mediated systemic disorder with a well-established genetic base. In a previous study, using a next generation sequencing approach, we found many rare variants and some functional polymorphisms in genes related to autoinflammatory syndromes (AID): CECR1, MEFV, MVK, NLRP3, NOD2, PSTPIP1 and TNFRSF1A in our BD cohort. Our strategy did not allow us to establish either number of patients with variants, proportion of individuals accumulating them or relationship with other genetic factors. With the goal to answer these questions, the individual samples were sequenced. Additionally, three functional polymorphisms: NLRP3 p.Gln703Lys, NOD2 p.Arg702Trp and p.Val955Ile were genotyped using TaqMan assays. A total of 98 patients (27.6%) carried at least one rare variant and 13 of them (3.7%) accumulated two or three. Functional regression model analysis suggests epistatic interaction between B51 and MEFV (P = 0.003). A suggestive protective association of the minor allele of NOD2 p.Arg702Trp (P = 0.01) was found in both, B51 positive and negative individuals. Therefore, a high percentage of patients with BD have rare variants in AID genes. Our results suggest that the association of MEFV with BD could be modulated by the HLA molecules; whereas the protective effect of NOD2 p.Arg702Trp would be independent of HLA.

8.
Clin Rheumatol ; 38(5): 1329-1337, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30588556

RESUMO

BACKGROUND: Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties. PATIENTS AND METHODS: Spanish RA (n = 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test. P values under 0.05 were considered to be significant. RESULTS: The concentration of PON1 in the RA group was higher than in control group (p = 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (p = 0.8501) or rs854860 (p = 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity. CONCLUSIONS: Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.

9.
Genome Med ; 10(1): 97, 2018 12 20.
Artigo em Inglês | MEDLINE | ID: mdl-30572963

RESUMO

BACKGROUND: In recent years, research has consistently proven the occurrence of genetic overlap across autoimmune diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. The objective of this study was to further investigate this shared genetic component. METHODS: For this purpose, we performed a cross-disease meta-analysis of Immunochip data from 37,159 patients diagnosed with a seropositive autoimmune disease (11,489 celiac disease (CeD), 15,523 rheumatoid arthritis (RA), 3477 systemic sclerosis (SSc), and 6670 type 1 diabetes (T1D)) and 22,308 healthy controls of European origin using the R package ASSET. RESULTS: We identified 38 risk variants shared by at least two of the conditions analyzed, five of which represent new pleiotropic loci in autoimmunity. We also identified six novel genome-wide associations for the diseases studied. Cell-specific functional annotations and biological pathway enrichment analyses suggested that pleiotropic variants may act by deregulating gene expression in different subsets of T cells, especially Th17 and regulatory T cells. Finally, drug repositioning analysis evidenced several drugs that could represent promising candidates for CeD, RA, SSc, and T1D treatment. CONCLUSIONS: In this study, we have been able to advance in the knowledge of the genetic overlap existing in autoimmunity, thus shedding light on common molecular mechanisms of disease and suggesting novel drug targets that could be explored for the treatment of the autoimmune diseases studied.


Assuntos
Doenças Autoimunes/genética , Predisposição Genética para Doença , Polimorfismo de Nucleotídeo Único , Artrite Reumatoide/genética , Doença Celíaca/genética , Diabetes Mellitus Tipo 1/genética , Estudo de Associação Genômica Ampla , Humanos , Anotação de Sequência Molecular , Escleroderma Sistêmico/genética
10.
Arthritis Rheumatol ; 2018 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-30277011

RESUMO

OBJECTIVES: The new RA-specific autoantibodies, the anti-carbamylated protein antibodies (ACarPA), provide an opportunity to improve management and understanding of RA. However, many questions remain about them, including their relationship with HLA-DRB1 alleles. MATERIAL AND METHODS: The samples of 1126 RA patients from three collections were obtained. Serum reactivity against in vitro carbamylated FCS proteins was determined by ELISA. HLA-DRB1 alleles were determined by either hybridization techniques or imputation from HLA dense genotypes. These results were combined by meta-analysis with data from three previously reported cohorts. The carrier frequencies of the common HLA-DRB1 alleles were compared between the antibody-positive subgroups and the double-negative subgroup in ACPA/ACarPA stratified patients, and between the four patient strata and the healthy controls. RESULTS: Meta-analysis was conducted with 3709 RA patients and 2305 healthy subjects. It revealed a significant increase of HLA-DRB1*03 carriers in the ACPA- /ACarPA+ subgroup in comparison with both ACPA- /ACarPA- patients and healthy controls that was consistent in the six sample collections. This association was independent of the SE and the analyzed confounders. No other allele was specifically associated with ACPA- /ACarPA+ patients. In contrast, the SE was significantly increased in the ACPA+ /ACarPA- and ACPA+ /ACarPA+ patient subgroups without distinction between them. Also, some alleles (including HLA-DRB1*03) were associated with protection from ACPA+ RA. CONCLUSION: A specific association of HLA-DRB1*03 with ACPA- /ACarPA+ RA has been identified that suggests preferential presentation of carbamylated peptides as a new mechanism for HLA contribution to RA susceptibility. This article is protected by copyright. All rights reserved.

11.
Clin Rheumatol ; 2018 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-30328025

RESUMO

The study aims to analyze the association between the bone and cartilage/periarticular components of the radiographic joint damage and disability over the course of disease, in a cohort of rheumatoid arthritis (RA) patients from a day-to-day clinical practice. The secondary aim is to study the role of demographic and disease-related variables in this association. We performed a retrospective longitudinal study including 736 RA patients. Disability was assessed with the health assessment questionnaire (HAQ), and radiographic joint damage of hands and wrists with the Sharp van-der-Heijde score (total (SHS), erosion (ES), and narrowing/(sub)luxation (NSLS) components]. Generalized estimating equations models, adjusted by disease activity, demographic and disease-related variables, were used to test the relationship between SHS and medium-term (median value of the HAQs performed in the following year after each radiograph) and long-term (set of HAQ measures performed during follow-up, at least 1 year apart from the first x-ray) disability. Interaction terms between the SHS and demographic and disease-related variables were introduced in the models. To account for multiple testing, Bonferroni correction was applied. NSLS was independently associated with medium-term disability, even after Bonferroni correction. We observed significant and positive interactions between NSLS and age at x-ray, and with the ES. SHS showed no association with long-term disability. The cartilage/soft tissue component of the radiographic joint damage seems to exert a much more important role in medium-term disability than the erosive component. This association could be modulated by the age at the x-ray and by the magnitude of the erosive damage.

12.
Arthritis Rheumatol ; 2018 Sep 24.
Artigo em Inglês | MEDLINE | ID: mdl-30251476

RESUMO

OBJECTIVE: A genome-wide association study (GWAS) was conducted to shed light into the genetic background influencing the development of cardiovascular (CV) disease in patients diagnosed with rheumatoid arthritis (RA). METHODS: After quality control and imputation, a total of 6,308,944 polymorphisms across the whole genome were analysed in 2,989 RA patients from European origin. Data on subclinical atherosclerosis, obtained by carotid ultrasonography through assessment of carotid intima-media thickness (cIMT) and presence/absence of carotid plaques, were available for 1,355 individuals. RESULTS: A genetic variant of the RARB gene (rs116199914) was associated with cIMT values at the genome-wide level of significance (minor allele (G): beta (ß) coefficient=0.142, P=1.86E-08). Interestingly, rs116199914 overlapped with regulatory elements in tissues related to CV pathophysiology and immune cells. In addition, biological pathway enrichment and predictive protein-protein relationship analyses, including suggestive GWAS signals of potential relevance, revealed a functional enrichment of the collagen biosynthesis network related to the presence/absence of carotid plaques (GO:0032964, PFDR =4.01E-03). Furthermore, our data suggest a potential influence of the previously described candidate CV risk loci NFKB1, MSRA and ZC3HC1 (P=8.12E-04, P=5.94E-04 and P=2.46E-04, respectively). CONCLUSION: Our study strongly suggests that genetic variation within RARB contributes to the development of subclinical atherosclerosis in patients with RA. This article is protected by copyright. All rights reserved.

13.
Arthritis Res Ther ; 20(1): 195, 2018 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-30157925

RESUMO

BACKGROUND: This study aimed to determine whether, besides carotid ultrasound (US), a lateral lumbar spine radiography may also help identify ankylosing spondylitis (AS) patients at high risk of cardiovascular (CV) disease. METHODS: A set of 125 AS patients older than 35 years without a history of CV events, diabetes mellitus, or chronic kidney disease was recruited. Carotid US and lateral lumbar spine radiography were performed in all of them. The CV risk was calculated according to the total cholesterol systematic coronary risk evaluation (TC-SCORE) algorithm. Presence of carotid plaques was defined following the Mannheim Carotid Intima-media Thickness and Plaque Consensus. Abdominal aortic calcium (AAC) in a plain radiography was defined as calcific densities visible in an area parallel and anterior to the lumbar spine. RESULTS: Carotid US showed higher sensitivity than lateral lumbar spine radiography to detect high CV risk in the 54 patients with moderate TC-SCORE (61% versus 38.9%). Using carotid plaques as the gold standard test, a predictive model that included a TC-SCORE ≥ 5% or the presence of AAC in the lateral lumbar spine radiography in patients with both moderate and low CV risk (< 5%) according to the TC-SCORE yielded a sensitivity of 50.9% with a specificity of 95.7% to identify high/very high CV-risk AS patients. A positive correlation between AAC and carotid plaques was observed (r2 = 0.49, p < 0.001). CONCLUSIONS: A lateral lumbar spine radiography is a useful tool to identify patients with AS at high risk of CV disease.

14.
Mediciego ; 24(2)jul.2018. Fig
Artigo em Espanhol | CUMED | ID: cum-71195

RESUMO

Introducción: la malformación de Chiari II es la más común dentro de los cuatro tipos de la clasificación y es la de mayor importancia clínica por su frecuente asociación con el mielomeningocele.Objetivo: presentar un caso cuya sintomatología resultó compatible con una malformación de Arnold Chiari tipo II, lo cual es útil como material de consulta para neonatólogos y neurocirujanos.Presentación del caso: neonato masculino, nacido por cesárea debido a desproporción céfalo-pélvica materna. La madre, residente en el Estado Plurinacional de Bolivia en un área alejada del centro de salud, acudió a solo a dos consultas prenatales. El tiempo de gestación fue de 39 semanas, el peso de 3 900 g y el puntaje de Apgar de 9/9. Llamó la atención el aumento de la circunferencia craneal y la presencia de un saco lumbar en protrusión por el que se veían las meninges y salía líquido cefalorraquídeo. Se cubrió la zona con apósito estéril y solución salina fisiológica, se inició el tratamiento con antibióticos de segunda línea y se realizó ultrasonido de cráneo transfontanelar.Conclusiones: ante un neonato con defecto lumbar y circunferencia cefálica superior al 90 percentil, el especialista debe tener en cuenta la posible existencia de malformaciones del sistema nervioso central (específicamente del tubo neural) e hidrocefalia como manifestaciones del síndrome de Arnold Chiari tipo II. Para confirmar el diagnóstico es útil, por su inocuidad e inmediatez, el ultrasonido de cráneo transfontanelar, y el neonato debe ser valorado por el especialista en neurocirugía para definir el tratamiento(AU)


Introduction: the Chiari II malformation is the most common within the four types of classification and is the most clinically important due to its frequent association with meningomyelocele.Objective: to present a case whose symptomatology was compatible with Arnold Chiari malformation type II, which is useful as reference material for neonatologists and neurosurgeons.Case presentation: male neonate, born by caesarean section due to maternal cephalopelvic disproportion. The mother, resident in the Plurinational State of Bolivia in an area far from the health center, attended only two prenatal consultations. The gestation time was 39 weeks, the weight of 3 900 g and the Apgar score of 9/9. The increase in the cranial circumference and the presence of a protruding lumbar sac through which the meninges were seen and cerebrospinal fluid came out attracted attention. The area was covered with sterile dressing and physiological saline solution, treatment with second-line antibiotics was started and ultrasound of the transfontanellar skull was carried out.Conclusions: before a neonate with lumbar defect and cephalic circumference greater than 90th percentile, the specialist must take into account the possible existence of malformations of the central nervous system (specifically the neural tube) and hydrocephalus as manifestations of the Arnold Chiari type II syndrome. To confirm the diagnosis, it is useful, because of its innocuousness and immediacy, the transfontanellar skull ultrasound, and the neonate must be evaluated by the specialist in neurosurgery to define the treatment(AU)


Assuntos
Humanos , Masculino , Recém-Nascido , Região Lombossacral , Meningomielocele , Hidrocefalia , Malformação de Arnold-Chiari/diagnóstico , Relatos de Casos
15.
Int J Rheumatol ; 2018: 1847894, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29666651

RESUMO

Objective: To determine if the use of the relative risk (RR) chart score may help to identify young ankylosing spondylitis (AS) patients at high risk of cardiovascular (CV) disease. Methods: 73 AS patients younger than 50 years were assessed. CV risk was calculated according to the total cholesterol systematic coronary risk evaluation (TC-SCORE) and the RR chart score. C-reactive protein (CRP) value at disease diagnosis and carotid ultrasound data were also analyzed. Results: Twenty (27.4%) patients exhibited carotid plaques being classified into the category of very high CV risk. None of them was found to have a high/very high TC-SCORE. CRP > 3 mg/L at disease diagnosis was associated with the presence of carotid plaques (odds ratio 5.66, p = 0.03). Whereas only 5 (14.2%) of the 35 patients with RR = 1 had carotid plaques, 15 (39.5%) of 38 with RR > 1 showed plaques. A model that included the performance of carotid US in patients with RR > 1 who had CRP > 3 mg/L allowed us to identify 60% of very high risk patients, with a specificity of 77.4%. Conclusions: RR chart score assessment may help to identify young AS patients at high risk of CV disease.

16.
J Clin Rheumatol ; 2018 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-29561466

RESUMO

OBJECTIVE: The aim of this study was to assess the reliability and validity of the Spanish version of the Rosser classification system for disease states in patients with musculoskeletal disorders. METHODS: Our study was based on a questionnaire validation design. Patients were attended at an outpatient rheumatology clinic at Hospital Clínico San Carlos, Madrid, Spain. The Rosser classification system was completed by the physician from the research team (PMQ) and by the patient (HMQ). Criterion standards: The EuroQol-5D for the HMQ and the physician global estimate (DOCGL) for the PMQ. Internal consistency reliability was assessed using Cronbach α. Test-retest reliability and interobserver reliability were analyzed using the intraclass correlation coefficient. The criterion validity between HMQ and EuroQol-5D and between PMQ and DOCGL was assessed using the Spearman correlation coefficient. RESULTS: The full analysis was based on 4 samples of patients (104 to 266 patients), most of whom were middle-aged women. For HMQ, Cronbach α was 0.70. Test-retest reproducibility was 0.7. With respect to criterion validity, significant correlations in the expected direction were observed. For PMQ, Cronbach α was 0.70, indicating excellent intraobserver and interobserver reliability. With respect to criterion validity, strong correlations were observed between the PMQ and the DOCGL. CONCLUSIONS: The Rosser classification system showed satisfactory reliability and suitable criterion validity for patients with musculoskeletal disorders. The instrument seems to be suitable for clinical decision making and research.

17.
Mediciego ; 23(4)mar.2018. fig
Artigo em Espanhol | CUMED | ID: cum-69603

RESUMO

Introducción: el quilotórax congénito es una rara condición respiratoria, sin embargo es la causa más frecuente de derrame pleural en recién nacidos. Su incidencia es baja, aproximadamente 1:10 000-15 000 recién nacidos vivos. Las propuestas de tratamiento abarcan las opciones conservadora, medicamentosa y quirúrgica.Objetivo: presentar el caso de un recién nacido con quilotórax congénito tratado con suspensión de la alimentación oral y administración parenteral de aminoácidos de cadena media y ácidos grasos de cadena corta o media al reiniciar la alimentación enteral.Presentación del caso: paciente masculino, primer gemelar pretérmino y bajo peso, con síndrome parabiótico. A los 21 días de vida presentó derrame pleural izquierdo. Se puncionó y el estudio del líquido drenado mostró características propias del quilotórax. Se le indicó tratamiento conservador, con alimentación parenteral completa, y posteriormente con leche rica en ácidos grasos de cadenas corta y media. Una vez recuperado se le dio el alta hospitalaria.Conclusiones: ante un neonato que presente signos clínicos y radiológicos de derrame pleural se debe pensar en la posibilidad de un quilotórax, por lo que es indispensable evacuar el líquido para su estudio. Una vez confirmado el diagnóstico se sugiere la suspensión de la alimentación por vía oral y administrar aminoácidos de cadena media por vía parenteral. El reinicio de la alimentación enteral debe ser con ácidos grasos de cadena corta o media, sin ácidos grasos de cadena larga, para evitar las recidivas(AU)


Introduction: congenital chylothorax is a rare respiratory condition, however it is the most frequent cause of pleural effusion in newborns. Its incidence is low, approximately 1:10 000-15 000 live births. Treatment proposals include conservative, drug and surgical options.Objective: to present the case of a newborn with congenital chylothorax treated with suspension of oral feeding and parenteral administration of medium chain aminoacids and short or medium chain fatty acids upon reinitiation of enteral feeding. Case presentation: male patient, first preterm twins and low weight, with parabiotic syndrome. At 21 days of life he presented left pleural effusion. It was punctured and the study of drained fluid showed characteristics of chylothorax. Conservative treatment was indicated, with complete parenteral feeding, and later with milk rich in fatty acids of short and medium chains. Once recovered, he was discharged from hospital.Conclusions: in the presence of a neonate presenting clinical and radiological signs of pleural effusion, the possibility of a chylothorax should be considered, so it is essential to evacuate the fluid for study. Once the diagnosis is confirmed, it is suggested to suspend the oral feeding and administer medium chain amino acids parenterally. The restart of enteral feeding should be with short or medium chain fatty acids, without long-chain fatty acids, to avoid recurrence(AU)


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Quilotórax/diagnóstico , Quilotórax/epidemiologia , Relatos de Casos
18.
Clin Exp Rheumatol ; 36 Suppl 111(2): 121-128, 2018 Mar-Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29303708

RESUMO

OBJECTIVES: To assess the incidence and the risk of relapses in giant cell arteritis (GCA) patients treated with and without methotrexate (MTX) in clinical practice. Other associated factors were also investigated. METHODS: An inception cohort of GCA was assembled in the out-patient clinic at Hospital Clínico San Carlos, including patients from the date of diagnosis (Jan-1991 until Sept-2013), and followed-up until lost of follow up or Sept-2014. MAIN OUTCOME: relapse defined as recurrence of symptoms or signs of GCA with high ESR and the need to increase glucocorticoids at least 10mg over the previous dose. The independent variable was exposure to MTX over time. Covariables: Sociodemographic, clinical, and treatment. Incidence rates of relapses (IR) per 100 patient-year with their 95% confidence intervals [CI] were estimated using survival techniques. MTX influence on relapses was analysed by Cox models. RESULTS: 168 patients were included (675 patient-year). 31% of patients had relapses (IR of 12 [9.6-14.9]), and the median number of relapses was 1[1-2]. 65% of the patients were on MTX, (mean dose: 10mg). In the bivariate analysis, the risk of relapses in patients with and without MTX did not achieve statistical signification (p=0.1). After adjusting in the multivariate analysis, exposure to MTX had 72% less risk of relapse compared to those without MTX (p<0.05). Other variables included in the final model were: visual alterations and malaise at clinical presentation of GCA. CONCLUSIONS: The use of MTX seems to decrease the risk of recurrences. We also found other factors influencing on relapses.


Assuntos
Antirreumáticos/uso terapêutico , Arterite de Células Gigantes/tratamento farmacológico , Metotrexato/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Sedimentação Sanguínea , Quimioterapia Combinada , Feminino , Arterite de Células Gigantes/sangue , Glucocorticoides/administração & dosagem , Humanos , Incidência , Masculino , Análise Multivariada , Modelos de Riscos Proporcionais , Recidiva , Risco
19.
Clin Exp Rheumatol ; 36(1): 29-35, 2018 Jan-Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28598787

RESUMO

OBJECTIVES: Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. METHODS: A 14-year retrospective longitudinal study was performed. RA patients followed in an out-patient clinic starting bDMARDs after the age of 65 were included. PRIMARY OUTCOME: discontinuation due to a severe ADR related to bDMARDs (etanercept, infliximab, adalimumab, rituximab, golimumab, certolizumab, abatacept and tocilizumab). Covariables: sociodemographic, clinical and therapy. Incidence rates of discontinuation were estimated using survival techniques and comparison between bDMARDs discontinuation rates and other associated factors were run by Cox regression models. RESULTS: We analysed 286 courses of bDMARDs therapy in 146 elderly patients (604 patient-years). 78% were women, with a mean age at diagnosis of 66.5±7 years, and a median time to the start of the first bDMARDs of 6±4 years. The incidence of discontinuation due to severe ADR estimated was 10.2% patient-years, with a median survival of around 7 years. The most frequent cause was infections. Etanercept had the lowest risk of severe ADR compared to other bDMARDs. CONCLUSIONS: Our study reflects the 'real world' experience in elderly RA patients on bDMARDs, with non-selected patients for a 14-year follow-up.


Assuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Produtos Biológicos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Fatores Etários , Idoso , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/imunologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/imunologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Incidência , Estimativa de Kaplan-Meier , Estudos Longitudinais , Masculino , Análise Multivariada , Infecções Oportunistas/epidemiologia , Infecções Oportunistas/imunologia , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Espanha/epidemiologia , Resultado do Tratamento
20.
Ophthalmologica ; 239(2-3): 151-158, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29241207

RESUMO

PURPOSE: To report the incidence rate (IR) of remission in pediatric noninfectious intermediate uveitis (IU). METHODS: Longitudinal retrospective cohort study, including 19 patients (32 eyes) between 1985 and 2014, followed-up until loss or January 2016. Remission was defined following the Standardization of Uveitis Nomenclature workshop criteria, prolonged remission as a remission spanning 12 months and until the end of follow-up, and relapse as recurrence of inflammatory activity in an eye in remission. RESULTS: Median follow-up time was 6.3 years. IRs (95% confidence interval) for remission, relapse, and prolonged remission were 18.6 (13.1-26.5), 32.3 (20.6-50.7), and 6.7 (3.8-11.9) episodes per 100 eye-years, respectively. 48% of eyes relapsed in the first year following remission. 25 and 50% of eyes achieved prolonged remission after 5 and 10 years of follow-up, respectively. CONCLUSIONS: Inflammatory relapses may be frequent in noninfectious IU affecting children and adolescents, appearing early after remission. Also, prolonged remission seems infrequent, being achieved late during follow-up.


Assuntos
Uveíte Intermediária/epidemiologia , Acuidade Visual , Adolescente , Criança , Doença Crônica , Feminino , Seguimentos , Humanos , Masculino , Morbidade/tendências , Recidiva , Remissão Espontânea , Estudos Retrospectivos , Fatores de Risco , Espanha/epidemiologia , Análise de Sobrevida , Fatores de Tempo , Uveíte Intermediária/diagnóstico , Uveíte Intermediária/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA